WO1993003054A1 - Novel tetrapeptide derivative - Google Patents
Novel tetrapeptide derivative Download PDFInfo
- Publication number
- WO1993003054A1 WO1993003054A1 PCT/JP1992/001005 JP9201005W WO9303054A1 WO 1993003054 A1 WO1993003054 A1 WO 1993003054A1 JP 9201005 W JP9201005 W JP 9201005W WO 9303054 A1 WO9303054 A1 WO 9303054A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- reference example
- mmol
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel tetrabeptide derivatives having antitumor activity
- R 2 , R 3 and R 4 are the same or different and each represent a hydrogen atom, a lower alkyl group or an aralkyl group;
- Q represents —Al or one A 2 —R 7 group, where
- A represents a direct bond or one CH-
- Y represents a hydrogen atom or one C OR e
- R 5 represents a hydrogen atom, a lower alkyl group or Ararukiru
- R 6 is human Dorokishi group, a lower alkoxy group, Aralkyloxy or Re
- R 9 is selected from hydrogen, lower alkyl, phenyl or S, 0 and N Represents a 4- to 7-membered heterocyclic group containing one or two heteroatoms,
- R 8 and R 9 form a heterocyclic ring they still Te summer together with the nitrogen atom bonded S, 0 c and one of may also be 4-7 membered contain heteroatoms selected from N May be represented),
- a 2 represents a direct bond or a lower alkylene group
- R 7 represents a cycloalkyl group, aryl group or indolyl group, provided that R t and R 2 represent an isopropyl group, R 3 represents a sec-butyl group, R 4 represents a methyl group, and Q represents Excluding the case of representing a (2-thiazolyl) phenethyl group,
- dolastatin 10 is a pentapeptide having the following structural formula, extracted from Indian sea snails by Petit et al., 1987, and has the strongest production of cell growth inhibition among known compounds (Petit et al., Journal of the American Chemical Society (J. Am. Chem. Soc.), 109, 6883, (18987) Year) and Japanese Patent Application Laid-Open No. 2-1677278). . CH 3 ° CH3 °
- Dorastatin 10 Also, in recent years, the total synthesis of Dorastin 10 itself has been announced (see Patent No. 4,978,764), but with respect to its derivatives, Not known at all so far.
- dolastatin 10 derivatives of dolastatin 10.
- dolastatin 10 analogs represented by the above formula (I) have a higher cell growth controlling action than dolastatin 10.
- many of these compounds were found to be superior anti-tumor agents because of their higher therapeutic ratio (maximum effective dose / dose of 30% survival rate) and lower toxicity than dolastatin 10.
- alkyl group may be linear or branched, and may be, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl,
- aralkyl group means an aryl-lower alkyl group, such as a benzyl or phenethyl group.
- the “lower alkoxy group” is a lower alkyl 10-group in which the lower alkyl moiety has the above-mentioned meaning, and includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy and the like.
- An "aralkyloxy group” is an aralkyl-10-group in which the aralkyl moiety has the above-mentioned meaning, and includes, for example, a benzyloxy, phenethyloxy group and the like.
- the “lower alkylene group” may be linear or branched, and includes, for example, methylene, ethylene, trimethylene, tetramethylene, methylmethylene, propylene, ethylethylene, 1,2-dimethyl Ethylene group and the like;
- alkyl group include cycloalkyl groups having 3 to 7 carbon atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, and cycloheptyl groups.
- Examples of the "aryl group” include phenyl and naphthyl. And the like.
- heterocyclic group of R 8 or R 9 which represents “a 4- to 7-membered heterocyclic group containing 1 or 2 hetero atoms selected from S, 0 and N”
- examples include azetidinyl, furyl, chenyl, pyridyl, piberidinyl, azevinyl, thiazolyl, imidazolyl, oxazolyl, pyrimidinyl, and pyridazinyl groups, while R 8 and R 9 are ⁇ joined together with the nitrogen atom to which they are bonded.
- a 4- to 7-membered heterocyclic ring which may further contain one heteroatom selected from S, O and N '', examples of the heterocyclic ring include azetidino, hiroridino , Piperidino, 1-perhydrodroazepinyl, hyperazino, morpholino, thiomorpholino and the like.
- examples of 1N groups include amino, methylamino, and amino.
- Cylamino isopropylamino, tert-butylamino, dimethylamino, dimethylamino, phenylamino, ⁇ -methyl-phenylamino, furylamino, pyridylamino, 2-thiazolylamino, imidazolylamino, pyrimidinylamino, pyrrolidino, piperidino, etc. it can.
- a preferred group of compounds of the formula (I) is that Q is E 5
- R 2 , R 3 , R 4 and R 5 are dolastatin 10 (Ri and R 2 are isopropynole groups, R 3 is sec-butyl group, and R 4 is methyl a group, represent the same groups as R 5 Gabe Njiru compound is a group), only the remaining one group is different from dolastatin 10 group compounds when you'll Table are especially preferred.
- Ri and R 2 represent an isopropyl group
- R 3 represents a sec-butyl group
- R 4 represents a methyl group
- Another preferred group of compounds are compounds wherein Q represents -A 2 -R 7 ⁇ , wherein A 2 represents a lower alkylene group, and R 7 has the meaning given above. among others, and R 2 is Table Wa the Isopuropiru group, 1 3 represents a 3 ec one butyl group, R 4 represents a methyl group, and the compound R 7 represents a ⁇ re Ichiru group is preferred Ride.
- the carbon atoms to which the substituents Rt, R 2 , R 3 , R 4 and R 5 and the methoxy group are bonded are asymmetric carbon atoms. It can have any R or S configuration, and they are all included in the scope of the present invention. However, from the viewpoint of pharmacological activity, a compound having the same configuration as dolastatin 10 is preferable.
- Me is a methyl group
- Et is an ethyl group
- Pr is a propyl group
- Bu is a butyl group
- Pe is a pentyl group
- Bz1 is a benzyl group
- Ph is a phenyl group
- Np is It means a naphthyl group.
- the tetradibutide derivative of formula (I) may exist as a salt, and examples of such a salt include hydrochloride, hydrobromide, trifluoroacetate, p-toluenesulfonate, acetate Can be mentioned.
- the tetrapeptide derivative of the formula (I) can be prepared by, for example, a liquid phase synthesis method well-known in the field of peptide chemistry (“The Pepties”, Vol. 1, by Lee Schroeder and Gay Lupke). , 76-: p. 136, published by Ademic Press in 1965), and can be produced by condensing each amino acid or peptide fragment.
- R 4 has the above-mentioned meaning, and Q represents a group of —Al ⁇ C N jl ′ or one A 2 —R ′, wherein a hydrogen atom or a methoxycarboe group is represented,
- a i. A 2 and R 7 have the above-mentioned meaning
- reaction is generally carried out in an inert solvent, such as chloroform, ethyl ether, tetrahydrofuran (THF), dimethylformamide (DMF), acetone, etc.
- an organic base such as triethylamine,
- DIEA diisopropylethylamine
- condensing agents such as dicyclohexylcarpoimide (DCC) diphenylphosphoryl azide (DPPA), getyl cyanophosphate (D EPC), which can be performed by treating with a so-called BOP reagent, etc.
- the reaction temperature is usually about 1 ° C to room temperature, preferably about 0 ° C,
- each of the compound of the formula (III), the organic base and the condensing agent to the compound of the formula (II) is such that at least 1 mol of the compound of the formula (III) per mol of the compound of the formula (II), preferably It is advantageous to use about 1.0 to 1.1 mol, about 2 mol of the organic base and about equimolar of the condensing agent.
- Conversion of the compound representing the 4 ones substituent Y turtles butoxycarbonyl group thiazole ring in the group Q to a compound represents a group one CO- R e is, For example, if R 6 represents a hydroxy group Al force When R 6 represents another lower alkoxy group or an aralkyloxy group, the compound in the case where R 6 represents a hydroxy group is esterified according to a conventional method. While R e is R 8
- the desired tetrabeptide derivative of the formula (I) is produced, and the isolation and purification from the reaction mixture are performed by recrystallization, ion exchange chromatography, gel filtration, high performance liquid chromatography, etc. It can be carried out.
- the compounds of the formulas (II) and ( ⁇ ) used as starting materials in the reaction are novel compounds that have not been described in conventional literatures, and their constituent amino acids are converted to a liquid phase. It can be easily produced by condensing with a synthetic method.
- the tetrapeptide derivative of the formula (I) of the present invention has a higher cell growth inhibitory effect than dolastatin 10, and is effective for acute myeloid leukemia, acute lymphocyte leukemia, chronic melanoma, lung adenocarcinoma, neuroblastoma, It is useful for treating small cell lung cancer, breast cancer, colon cancer, ovarian cancer, and bladder cancer.
- Dolastatin 10 7 OXL 0 compound according to one 4 present invention, when used as a drug, depending on the application, Solid form (eg, tablets, hard capsules, soft capsules, granules, powders, fine granules, pills, troches, etc.), semi-solid form (eg, suppositories, ointments, etc.) or liquid form (injections, emulsions) , Suspensions, lotions, sprays, etc.).
- Solid form eg, tablets, hard capsules, soft capsules, granules, powders, fine granules, pills, troches, etc.
- semi-solid form eg, suppositories, ointments, etc.
- liquid form injections, emulsions
- Suspensions lotions, sprays, etc.
- Non-toxic additives that can be used in the above-mentioned preparations include, for example, starch, gelatin, glucose, lactose, fructose, maltose, magnesium carbonate, talc, magnesium stearate, methylcellulose, carboxymethylcellulose or the like. Salt, gum arabic, polyethylene glycol, alkyl p-hydroxybenzoate, syrup, ethanol, propylene glycol, cellulose, carbox, glycerin, sodium chloride, sodium sulfite, sodium phosphate, citric acid and the like.
- the agent may also contain other therapeutically useful agents.
- the content of the compound of the present invention in the medicament varies depending on the dosage form, but it is generally in a concentration of 0.1 to 50% by weight in solid and semi-solid forms, and in a liquid form. It is desirable to contain it at a concentration of 0.05 to 10% by weight.
- the dose of the compound of the present invention can be varied widely depending on the kind of human or other warm-blooded animals, the administration route, the severity of the symptoms, the diagnosis of a doctor, etc. It can be about 1 to 50 mg Z kg. However, it is, of course, possible to administer an amount smaller than the lower limit or larger than the upper limit of the above range depending on the severity of the symptoms of the patient and the diagnosis of a doctor as described above.
- the above dose can be administered once or divided into several times.
- Reference Examples 2-B, 2-C, 2-D and 2-E were carried out in exactly the same manner as Reference Example 2-A to obtain compounds 2-B, 2-C, 2_D and 2-E.
- Reference Example 3-B, 3-C. 3-D and 3-E were performed in exactly the same manner as Reference Example 3-A to obtain compounds 3_B, 3-C and 3-D. 3-E as oils, respectively.
- Reference example Compound R 3 yield [] D-end J H-NMR (CDCl 3, ⁇ )
- reaction mixture is poured into a saturated aqueous solution of sodium bicarbonate, nitrogen gas is blown in to remove isobutene and most of dichloromethane, and the precipitated oil is extracted with ethyl sulphate.
- the ethyl acetate layer is washed with saturated aqueous sodium bicarbonate and dried. .
- the solvent was distilled off, and the remaining yellow oil (7.32 g) was subjected to silica gel chromatography (eluent:
- Reference example 41 Compound 4-AO. 70 g (2.00 mmol) obtained in 1A was dissolved in 20 ml of t-butanol / water (9: 1), 0.1 g of 5% palladium on carbon was added, and the mixture was stirred under a hydrogen stream for 2 hours. I do. After the reaction, the catalyst is filtered off and washed, and the filtrate is concentrated under reduced pressure. Dissolve the remaining oil in 30 ml of benzene, concentrate again under reduced pressure, and repeat this operation one more time.
- the obtained oil was dissolved in 1 Om 1 of acetonitrile together with 0.56 g (2.23 mmol) of Z-valine, and 0.43 g (2.09 mmol) of DCC was added under ice-cooling and stirring. Soon crystals precipitate. Leave the mixture at 0 ° for at least 3 hours, then let it melt on ice, continue stirring overnight, then dilute the reaction solution with ethyl acetate, filter the crystals, and wash with ethyl acetate.
- Reference Example 5 Compound 5—AO.
- 65 g (1.44 mmol) obtained in A was dissolved in 15 ml of t-butanol / water (9: 1), 50 mg of 5% palladium on carbon was added, and the mixture was stirred under a stream of hydrogen for 2 hours. I do.
- the catalyst is separated by filtration, washed, and the filtrate is concentrated under reduced pressure. Dissolve the oily residue in 30 ml of benzene, concentrate again under reduced pressure, and repeat this operation one more time.
- the obtained oil was dissolved in 6 ml of dimethylformamide, and 0.25 g (1.72 mmol) of N, N-dimethylvaline and 0.29 g (l.
- 6-D 6-D > CH- H> CH- 90, 3% oil (26 °) 3.37 (3H, s), 3.8 to 4.0 (1H, ra),
- the solvent was distilled off under reduced pressure, and the obtained crude product was purified by silica gel column chromatography using dichloromethane-methanol (50: 1) as an eluent. 262 mg (94.4%) of the target compound 11-A was obtained as an amorphous powder.
- Example compound 'R 2 R 3 R 4 R 5 Optical rotation MS ⁇ -MR (CD 2 C 12 , ⁇ )
- Example 2 14 one continued e
- Example Compound R 2 3 R 4 optical rotation MS 'H-NMR (CD 2 C1 2, ⁇ )
- the crude product is separated by preparative TLC using dichloromethane-methanol (10: 1) as a developing solvent, and the target fraction is further eluted with hexane: dichloromethane / methanol (2: 7.5: 2.5) ' Purified by Sephadex LH-20 chromatography and the target compound 16-J 13.7mg (57.7%) as amorphous ⁇ powder.
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK92916961T DK0598129T3 (da) | 1991-08-09 | 1992-08-06 | Nye tetrapeptidderivater |
US08/190,194 US6004934A (en) | 1991-08-09 | 1992-08-06 | Tetrapeptide derivative |
AT92916961T ATE190983T1 (de) | 1991-08-09 | 1992-08-06 | Neue tetrapeptidderivate |
AU24152/92A AU662551B2 (en) | 1991-08-09 | 1992-08-06 | Novel tetrapeptide derivative |
DE69230824T DE69230824T2 (de) | 1991-08-09 | 1992-08-06 | Neue tetrapeptidderivate |
KR1019940700418A KR0185440B1 (ko) | 1991-08-09 | 1992-08-06 | 신규의 테트라 펩티트 유도체 |
EP92916961A EP0598129B1 (en) | 1991-08-09 | 1992-08-06 | Novel tetrapeptide derivative |
CA002115355A CA2115355C (en) | 1991-08-09 | 1992-08-06 | Novel tetrapeptide derivative |
KR1019980707541A KR100202474B1 (en) | 1991-08-09 | 1998-09-23 | Novel tetrapeptide derivative |
GR20000401085T GR3033397T3 (en) | 1991-08-09 | 2000-05-11 | Novel tetrapeptide derivative. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3/223534 | 1991-08-09 | ||
JP22353491 | 1991-08-09 | ||
JP22539191 | 1991-08-12 | ||
JP3/225391 | 1991-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993003054A1 true WO1993003054A1 (en) | 1993-02-18 |
Family
ID=26525532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/001005 WO1993003054A1 (en) | 1991-08-09 | 1992-08-06 | Novel tetrapeptide derivative |
Country Status (13)
Country | Link |
---|---|
US (2) | US6004934A (ja) |
EP (2) | EP0598129B1 (ja) |
JP (1) | JP2618597B2 (ja) |
KR (2) | KR0185440B1 (ja) |
AT (2) | ATE215962T1 (ja) |
AU (2) | AU662551B2 (ja) |
CA (1) | CA2115355C (ja) |
DE (2) | DE69232552T2 (ja) |
DK (2) | DK0934950T3 (ja) |
ES (2) | ES2144421T3 (ja) |
GR (1) | GR3033397T3 (ja) |
SG (1) | SG87056A1 (ja) |
WO (1) | WO1993003054A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013695A1 (en) * | 1992-12-16 | 1994-06-23 | Basf Aktiengesellschaft | Dolostatin analog |
WO1995009864A1 (fr) * | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Nouveau derive peptidique |
US5840699A (en) * | 1995-04-21 | 1998-11-24 | Teikoku Hormone Mfg. Co. Ltd. | Peptide derivatives |
US5939527A (en) * | 1996-07-30 | 1999-08-17 | Basf Aktiengesellschaft | Tetrapeptides as antitumor agents |
KR20010079252A (ko) * | 2001-06-27 | 2001-08-22 | 홍진의 | 주름형 드럼을 갖는 드럼 필터 |
WO2003026645A1 (fr) * | 2001-09-20 | 2003-04-03 | Teikoku Hormone Mfg. Co., Ltd. | Cristaux d'un derive de tetrapeptide |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1390393A2 (en) * | 2001-04-30 | 2004-02-25 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7745394B2 (en) | 2003-11-06 | 2010-06-29 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
JP2015530403A (ja) * | 2012-09-20 | 2015-10-15 | セルトリオン, インク. | ドラスタチン10誘導体、その製造方法およびそれを含む抗癌剤組成物 |
JP2017519740A (ja) * | 2014-05-28 | 2017-07-20 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
WO2017170637A1 (ja) * | 2016-03-29 | 2017-10-05 | 東レ株式会社 | ペプチド誘導体及びその用途 |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA45304C2 (uk) * | 1992-05-20 | 2002-04-15 | Басф Аг | Похідні пептиду або їх солі, фармацевтична композиція |
US5831002A (en) * | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
US5599902A (en) * | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) * | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5807984A (en) * | 1995-11-09 | 1998-09-15 | Basf Aktienegesellschaft | Oligopeptides, the preparation and use thereof |
US20010009901A1 (en) | 1996-12-11 | 2001-07-26 | Basf Aktiengesellschaft Germany | Antineoplastic peptides |
US5741892A (en) * | 1996-07-30 | 1998-04-21 | Basf Aktiengesellschaft | Pentapeptides as antitumor agents |
US5965537A (en) * | 1997-03-10 | 1999-10-12 | Basf Aktiengesellschaft | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus |
US6103698A (en) | 1997-03-13 | 2000-08-15 | Basf Aktiengesellschaft | Dolastatin-15 derivatives in combination with taxanes |
US6143721A (en) | 1997-07-18 | 2000-11-07 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
CA2298639C (en) * | 1997-09-24 | 2005-07-05 | Erik J. Flahive | Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same |
US6686445B1 (en) | 1997-09-24 | 2004-02-03 | Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University | Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same |
US6015790A (en) * | 1997-10-06 | 2000-01-18 | Basf Aktiengesellschaft | Methods and compositions for treating rheumatoid arthritis |
US5985837A (en) * | 1998-07-08 | 1999-11-16 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
US6323315B1 (en) * | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
WO2001041789A1 (fr) * | 1999-12-07 | 2001-06-14 | Santen Pharmaceutical Co., Ltd. | Medicament contre les rhumatismes contenant un derive tetrapeptidique en tant qu'ingredient actif |
JP2008519863A (ja) * | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | N末端にアミノ安息香酸単位を有するオーリスタチン |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス, インコーポレイテッド | フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物 |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
US20090035848A1 (en) * | 2007-08-03 | 2009-02-05 | Robert Hickey | Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products |
WO2009117531A1 (en) * | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
EP2534170B1 (en) | 2010-02-12 | 2017-04-19 | Pharmascience Inc. | Iap bir domain binding compounds |
KR101733853B1 (ko) | 2011-11-17 | 2017-05-08 | 화이자 인코포레이티드 | 세포독성 펩티드 및 그의 항체 약물 접합체 |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
CN105899526A (zh) | 2013-12-17 | 2016-08-24 | 诺华股份有限公司 | 细胞毒性肽和其缀合物 |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
MX2016016515A (es) | 2014-06-13 | 2017-04-27 | Novartis Ag | Derivados de auristatina y conjugados de los mismos. |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
EP3325497B1 (en) | 2015-07-24 | 2020-09-02 | Arizona Board of Regents on behalf of Arizona State University | Quinstatin compounds |
US10722593B2 (en) | 2015-10-02 | 2020-07-28 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
KR102459468B1 (ko) | 2016-11-14 | 2022-10-26 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
US20230000995A1 (en) * | 2019-10-28 | 2023-01-05 | Ariel Scientific Innovations Ltd. | Dolastatin 10 analog |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5017691A (en) * | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US4978744A (en) * | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5635483A (en) * | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) * | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
-
1992
- 1992-08-06 SG SG9905131A patent/SG87056A1/en unknown
- 1992-08-06 DE DE69232552T patent/DE69232552T2/de not_active Expired - Fee Related
- 1992-08-06 WO PCT/JP1992/001005 patent/WO1993003054A1/ja active IP Right Grant
- 1992-08-06 US US08/190,194 patent/US6004934A/en not_active Expired - Fee Related
- 1992-08-06 AT AT98115259T patent/ATE215962T1/de not_active IP Right Cessation
- 1992-08-06 KR KR1019940700418A patent/KR0185440B1/ko not_active IP Right Cessation
- 1992-08-06 DE DE69230824T patent/DE69230824T2/de not_active Expired - Lifetime
- 1992-08-06 ES ES92916961T patent/ES2144421T3/es not_active Expired - Lifetime
- 1992-08-06 DK DK98115259T patent/DK0934950T3/da active
- 1992-08-06 EP EP92916961A patent/EP0598129B1/en not_active Expired - Lifetime
- 1992-08-06 EP EP98115259A patent/EP0934950B1/en not_active Expired - Lifetime
- 1992-08-06 DK DK92916961T patent/DK0598129T3/da active
- 1992-08-06 AU AU24152/92A patent/AU662551B2/en not_active Ceased
- 1992-08-06 JP JP5503479A patent/JP2618597B2/ja not_active Expired - Fee Related
- 1992-08-06 AT AT92916961T patent/ATE190983T1/de not_active IP Right Cessation
- 1992-08-06 CA CA002115355A patent/CA2115355C/en not_active Expired - Fee Related
- 1992-08-06 ES ES98115259T patent/ES2172069T3/es not_active Expired - Lifetime
-
1995
- 1995-05-12 AU AU20010/95A patent/AU673487B2/en not_active Ceased
- 1995-07-03 US US08/498,688 patent/US5654399A/en not_active Expired - Lifetime
-
1998
- 1998-09-23 KR KR1019980707541A patent/KR100202474B1/ko not_active IP Right Cessation
-
2000
- 2000-05-11 GR GR20000401085T patent/GR3033397T3/el not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
BAI R, PETIT G R, HAMEL E: "STRUCTURE-ACTIVITY STUDIES WITH CHIRAL ISOMERS AND WITH SEGMENTS OFTHE ANTIMITOTIC MARINE PEPTIDE DOLASTATIN 10", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 40, no. 08, 1 January 1990 (1990-01-01), US, pages 1859 - 1864, XP001057643, ISSN: 0006-2952, DOI: 10.1016/0006-2952(90)90367-T * |
PETTIT G R, ET AL.: "CHIRAL MODIFICATIONS OF DOLASTATIN 10: THE POTENT CYTOSTATIC PEPTIDE (19AR)-ISODOLASTATIN 10", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 33, no. 12, 1 January 1990 (1990-01-01), US, pages 3132/3133, XP001061672, ISSN: 0022-2623, DOI: 10.1021/jm00174a006 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013695A1 (en) * | 1992-12-16 | 1994-06-23 | Basf Aktiengesellschaft | Dolostatin analog |
WO1995009864A1 (fr) * | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Nouveau derive peptidique |
US5840699A (en) * | 1995-04-21 | 1998-11-24 | Teikoku Hormone Mfg. Co. Ltd. | Peptide derivatives |
US5939527A (en) * | 1996-07-30 | 1999-08-17 | Basf Aktiengesellschaft | Tetrapeptides as antitumor agents |
EP1390393A2 (en) * | 2001-04-30 | 2004-02-25 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1390393A4 (en) * | 2001-04-30 | 2006-05-24 | Seattle Genetics Inc | PENTAPEPTIDE COMPOUNDS AND USES THEREOF |
US7098308B2 (en) | 2001-04-30 | 2006-08-29 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
KR20010079252A (ko) * | 2001-06-27 | 2001-08-22 | 홍진의 | 주름형 드럼을 갖는 드럼 필터 |
WO2003026645A1 (fr) * | 2001-09-20 | 2003-04-03 | Teikoku Hormone Mfg. Co., Ltd. | Cristaux d'un derive de tetrapeptide |
US7385029B2 (en) | 2001-09-20 | 2008-06-10 | Teikoku Hormone Mfg. Co., Ltd. | Method of making tetrapeptide derivative TZT-1027 crystal |
US7008928B2 (en) | 2001-09-20 | 2006-03-07 | Teikoku Hormone Mfg. Co., Ltd. | Tetrapeptide derivative TZT-1027 crystal |
CN1309413C (zh) * | 2001-09-20 | 2007-04-11 | Aska制药株式会社 | 四肽衍生物的晶体 |
EP2357006A2 (en) | 2002-07-31 | 2011-08-17 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7829531B2 (en) | 2002-07-31 | 2010-11-09 | Seattle Genetics Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7851437B2 (en) | 2002-07-31 | 2010-12-14 | Seattle Genetics Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP2353611A2 (en) | 2002-07-31 | 2011-08-10 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US8906376B2 (en) | 2002-07-31 | 2014-12-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US10414826B2 (en) | 2003-11-06 | 2019-09-17 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US7745394B2 (en) | 2003-11-06 | 2010-06-29 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US8557780B2 (en) | 2003-11-06 | 2013-10-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US8703714B2 (en) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10808039B2 (en) | 2003-11-06 | 2020-10-20 | Seattle Genetics Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US11866496B2 (en) | 2007-07-16 | 2024-01-09 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
USRE48558E1 (en) | 2007-07-16 | 2021-05-18 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
JP2015530403A (ja) * | 2012-09-20 | 2015-10-15 | セルトリオン, インク. | ドラスタチン10誘導体、その製造方法およびそれを含む抗癌剤組成物 |
US11312748B2 (en) | 2014-05-28 | 2022-04-26 | Agensys, Inc. | Derivatives of dolaproine-dolaisoleucine peptides |
JP2020128405A (ja) * | 2014-05-28 | 2020-08-27 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
JP2017519740A (ja) * | 2014-05-28 | 2017-07-20 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
JP6995160B2 (ja) | 2014-05-28 | 2022-01-14 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
JP2022027896A (ja) * | 2014-05-28 | 2022-02-14 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
JP7292366B2 (ja) | 2014-05-28 | 2023-06-16 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
US10792365B2 (en) | 2016-03-29 | 2020-10-06 | Toray Industries, Inc. | Peptide derivative and use thereof |
JPWO2017170637A1 (ja) * | 2016-03-29 | 2019-02-07 | 東レ株式会社 | ペプチド誘導体及びその用途 |
WO2017170637A1 (ja) * | 2016-03-29 | 2017-10-05 | 東レ株式会社 | ペプチド誘導体及びその用途 |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP0598129A4 (en) | 1995-10-25 |
CA2115355A1 (en) | 1993-02-18 |
AU2415292A (en) | 1993-03-02 |
DE69232552D1 (de) | 2002-05-16 |
EP0598129A1 (en) | 1994-05-25 |
KR0185440B1 (ko) | 1999-04-01 |
EP0598129B1 (en) | 2000-03-22 |
EP0934950B1 (en) | 2002-04-10 |
AU673487B2 (en) | 1996-11-07 |
US6004934A (en) | 1999-12-21 |
EP0934950A1 (en) | 1999-08-11 |
DE69230824D1 (de) | 2000-04-27 |
KR100202474B1 (en) | 1999-06-15 |
US5654399A (en) | 1997-08-05 |
DE69230824T2 (de) | 2000-07-27 |
ES2172069T3 (es) | 2002-09-16 |
DK0598129T3 (da) | 2000-07-03 |
ATE190983T1 (de) | 2000-04-15 |
DK0934950T3 (da) | 2002-07-29 |
GR3033397T3 (en) | 2000-09-29 |
CA2115355C (en) | 2007-09-11 |
DE69232552T2 (de) | 2002-10-31 |
ATE215962T1 (de) | 2002-04-15 |
AU662551B2 (en) | 1995-09-07 |
JP2618597B2 (ja) | 1997-06-11 |
AU2001095A (en) | 1995-07-20 |
SG87056A1 (en) | 2002-03-19 |
ES2144421T3 (es) | 2000-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993003054A1 (en) | Novel tetrapeptide derivative | |
KR100408909B1 (ko) | 신규펩티드유도체 | |
JP6947644B2 (ja) | 重水素化ケノデオキシコール酸誘導体およびこの化合物を含む薬物組成物 | |
ES2461967T3 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
KR100332254B1 (ko) | 신규인펩티드유도체 | |
TW201943712A (zh) | 一種多功能化合物、其製備方法及其在醫藥上的應用 | |
WO1994008943A1 (en) | 2-amino-1,3-propanediol compound and immunosuppressant | |
FR2530626A1 (fr) | Composes de carbostyryle | |
KR20220052918A (ko) | 치료제로서의 사이토톡신의 펩티드 접합체 | |
WO2011003058A1 (en) | Prostacyclin derivatives | |
EP1979352A2 (fr) | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. | |
JPH0977791A (ja) | ペプチド誘導体及びその用途 | |
JPH06234790A (ja) | 新規テトラペプチドアミド誘導体 | |
WO2001021583A1 (fr) | Derives d'acide hydroxamique, procede de production desdits derives et medicaments contenant lesdits derives comme principe actif | |
CN104817559B (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
JP7292588B2 (ja) | Ccr2/ccr5アンタゴニストとしてのヘテロシクロアルキル系化合物 | |
WO2008092335A1 (fr) | Nouveaux dérivées de la vinblastine, leur préparation, et compositions pharmaceutiques les comprenant. | |
EP2896623A1 (en) | CRYSTAL OF N-[2-({2-[(2S)-2-CYANOPYRROLIDIN-1-YL]-2- OXOETHYL}AMINO)-2-METHYLPROPYL]-2-METHYLPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXAMIDE | |
TWI808786B (zh) | 酮類衍生物 | |
US4545936A (en) | Novel aminonaphthacene derivatives and process for preparation thereof | |
EP2163553A1 (en) | Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof | |
JPH05117280A (ja) | アミノ酸置換チアゼトキノリン−3−カルボン酸誘導体 | |
WO2022127915A1 (zh) | 吡啶并嘧啶酮类化合物 | |
WO2020038278A1 (zh) | 新型喜树碱衍生物及其制备方法和应用 | |
WO2024036305A2 (en) | Process for the preparation of 3-(3,5-difluoro-2-methoxyphenyl)-5-(1-(1-(methylsulfonyl)piperidin-4-yl)-1h-pyrazol-4-yl)-1h-pyrrolo[2,3-s]pyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992916961 Country of ref document: EP Ref document number: 1019940700418 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2115355 Country of ref document: CA Ref document number: 08190194 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992916961 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980707541 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992916961 Country of ref document: EP |